A Safer Solution for Postoperative GI Dysfunction and Opioid-induced Constipation
PCS12852 Targets GI Motility Disorders
PCS12852 is a novel, potent, and highly selective 5-HT4 receptor agonist for treating Gastrointestinal (GI) motility disorder, also called gastrointestinal dysfunction (POGD). These GI disorders take many forms, including chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia, and gastroparesis. GI mobility disorders that develop following GI surgery are the most common cause of prolonged hospital stays, leading to increased healthcare costs.
Other 5-HT receptor antagonists have been successful in treating GI motility disorders. However, these often have less 5-HT4 selectivity and are associated with cardiovascular side effects due to the drugs binding to other receptors. In contrast, PCS12852 has been shown in clinical trials to increase GI function with no serious adverse effects.
On August 19, 2020, we acquired an exclusive license from Yuhan Corporation to develop, manufacture, and commercialize PCS12852 globally except for South Korea.